Understanding Blood-Based MRD Testing: What It Means for Multiple Myeloma Care
Join Multiple Myeloma expert, Dr. Benjamin Derman, for an informative webinar on blood-based MRD testing and its evolving role in multiple myeloma care. This minimally invasive approach offers an additional tool for monitoring disease and understanding treatment response. Dr. Derman will discuss the latest research, explain how blood-based MRD testing works, and highlight its practical benefits for patients. Attendees will gain insights into how this testing can help guide discussions with their healthcare team, track progress over time, and stay informed about advances in multiple myeloma management.
Cindy introduces the agenda of the event and featured speaker Dr. Benjamin Derman
Dr. Derman talks about MRD testing
Type your questions in the chat and we will answer them!
Cynthia Cahoon, RN
Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Dr. Benjamin Derman
Benjamin Derman, MD, specializes in hematology and oncology. Dr. Derman is an expert in multiple myeloma and other plasma cell disorders, such as monoclonal gammopathy, amyloidosis, plasmacytoma, and POEMS syndrome. He also diagnoses and treats cancerous conditions and uses the most innovative techniques, including CAR T-cell therapy and stem cell transplantation to deliver long-term success for his patients. Along with his clinical practice, Dr. Derman remains committed to research. Currently, he is focused on identifying strategies that can lead to a possible cure for multiple myeloma, including using very sensitive tests that measure small amounts of residual cancer cells in the body called ‘minimal residual disease’ (MRD) to guide decision making. Dr. Derman is also investigating new methods and therapies designed to improve outcomes and quality of life for his patients. Additionally, he is interested in evaluating reasons for racial disparities in multiple myeloma outcomes to better understand and care for those patients. His work has been published in several peer-reviewed journals, including the Journal of Immunotherapy of Cancer, Blood, Blood Advances, Blood Cancer Journal, Leukemia and Lymphoma and British Journal of Haematology.